Quantcast

Latest Oligodendroglioma Stories

2009-10-26 07:00:00

MALVERN, Pa., Oct. 26 /PRNewswire/ -- Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23,...

2009-10-01 13:58:00

Chemotherapy alone is just as effective as radiation / New positive prognostic factor found Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Zrich showed that...

2009-09-02 06:30:00

BOSTON, Mass. and TUSTIN, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. The data from an ongoing Phase II study of Cotara in patients with recurrent GBM is being...

2009-04-07 15:39:26

A U.S. study indicates the use of the drug Avastin to treat a subgroup of recurrent brain tumors is safe and effective at delaying tumor progression. The retrospective study conducted at the Seattle Cancer Care Alliance involved 22 patients suffering from a recurrent malignant glioma known as alkylator-refractory anaplastic oligodendroglioma, for which there is no existing standard therapy. Avastin, known generically as bevacizumab, is the first approved therapy designed to inhibit...

2009-03-10 14:22:59

The final results of a clinical trial show adding chemotherapy to radiotherapy treatment for brain tumors can extend a patient's survival for up to five years. Researchers focused their study on the most common and aggressive brain tumor, glioblastoma.  For over 30 years, post-operative radiotherapy was the standard treatment, but only offered modest survival benefits -- about nine months. In the clinical trial, scientists gave patients the chemotherapy drug temozolomide in combination...

2009-03-09 13:53:12

German and Swiss scientists say they have used the combination of two drugs to achieve a substantial improvement in the treatment of certain brain tumors. The researchers led by Professor Dr. Ulrich Herrlinger of the University of Bonn treated 39 patients who had been diagnosed with a gliablastoma. The patients -- treated with a combination of temozolomide and lomustine -- survived on average 23.1 months, while with the standard therapy the mean would have been 14.6 months, the researchers...

2009-03-09 07:00:00

A Drug That Improves Survival, When Added to Temodar/Temodal, Would Earn a 65 Percent Patient Share in the U.S. and a 30 Percent Patient Share in Europe in Newly Diagnosed Glioblastoma Multiforme, According to a New Report from Decision Resources WALTHAM, Mass., March 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the...

2008-09-06 00:00:04

By The Associated Press WASHINGTON (AP) - Scientists have mapped the cascade of genetic changes that turn normal cells in the brain and pancreas into two of the most lethal cancers. The result points to a new approach for fighting tumors and maybe even catching them sooner.Genes blamed for one person's brain tumor were different from the culprits for the next patient, making the puzzle of cancer genetics even more complicated.But Friday's research also found that clusters of seemingly...

2008-07-23 09:00:21

TORONTO, July 23 /PRNewswire-FirstCall/ -- July 23, 2008 - Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it has initiated enrollment in the Phase III GLASS-ART Trial evaluating Neuradiab(TM), a monoclonal antibody conjugated to Iodine-131, as a front-line therapy for primary glioblastoma multiforme (GBM). The first patient was enrolled at the Preston Robert Tisch Brain Tumor...

2008-07-17 09:00:19

TORONTO, July 17 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today released progression free survival (PFS) data from two previously conducted Phase II trials of Neuradiab(TM) in glioblastoma multiforme (GBM) patients. As an exploratory endpoint of the single arm PhaseӚÓš II trials, the data...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related